The company reported revenues of $0.5 million for the third quarter of 2007, compared to revenues of $0.4 million for the same period last year. Revenues for the nine-month period ended September 30, 2007 were $2.2 million as compared to revenues of $2.0 million for the same period in 2006.
Total operating costs and expenses for the nine months ended September 30, 2007 were $31.0 million as compared to $24.5 million for the same period in 2006, an increase of $6.5 million.
Net loss for the nine months ended September 30, 2007 was $24.2 million, or $1.57 per basic and diluted share, as compared to a net loss of $21.1 million, or $1.87 per basic and diluted share, for the same period in 2006.
Brian Pereira, president and CEO of Amag Pharmaceuticals, said: “We are on track to file our NDA for ferumoxytol as an intravenous iron replacement therapeutic to treat iron deficiency anemia in patients with chronic kidney disease this quarter, which is an important milestone for the company. We are making steady progress in building the necessary infrastructure to support the potential product launch of ferumoxytol in the US.”